A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Clinical trial NCT06703606 · RECRUITING

Trial details

NCT number: NCT06703606
Sponsor: Pfizer
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Severe Hemophilia A

Start date: 2025-05-13
Primary completion: 2027-05-05
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.